MTNB
Income statement / Annual
Last year (2024), Matinas BioPharma Holdings, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Matinas BioPharma Holdings, Inc.'s net income was -$24.25 M.
See Matinas BioPharma Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$1.10 M |
$3.19 M |
$33.00 K |
$158.33 K |
$89.81 K |
$119.75 K |
$149.69 K |
$0.00 |
$194.49 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$16.68 M
|
$14.58 M
|
$14.36 M
|
$11.23 M
|
$6.79 M
|
$9.01 M
|
$52.64 K
|
$5.29 M
|
| Gross Profit |
$0.00
|
$1.10 M
|
-$13.49 M
|
-$14.55 M
|
-$14.20 M
|
-$11.14 M
|
-$6.67 M
|
-$8.86 M
|
-$52.64 K
|
-$5.10 M
|
| Gross Profit Ratio |
0
|
1
|
-4.23
|
-440.91
|
-89.69
|
-124.09
|
-55.68
|
-59.2
|
0
|
-26.21
|
| Research and Development Expenses |
$11.43 M
|
$14.49 M
|
$16.68 M
|
$14.58 M
|
$14.36 M
|
$11.23 M
|
$6.79 M
|
$9.01 M
|
$3.95 M
|
$5.29 M
|
| General & Administrative Expenses |
$8.73 M
|
$10.37 M
|
$11.10 M
|
$10.19 M
|
$10.01 M
|
$7.78 M
|
$7.98 M
|
$7.64 M
|
$4.31 M
|
$4.81 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.73 M
|
$10.37 M
|
$11.10 M
|
$10.19 M
|
$10.01 M
|
$7.78 M
|
$7.98 M
|
$7.64 M
|
$4.31 M
|
$4.81 M
|
| Other Expenses |
$4.43 M
|
$0.00
|
-$16.68 M
|
-$14.58 M
|
-$14.36 M
|
-$11.23 M
|
$56.55 K
|
$22.03 K
|
-$16.51 K
|
$19.63 K
|
| Operating Expenses |
$24.59 M
|
$24.86 M
|
$11.10 M
|
$10.19 M
|
$10.01 M
|
$7.78 M
|
$14.77 M
|
$16.65 M
|
$8.26 M
|
$10.11 M
|
| Cost And Expenses |
$24.59 M
|
$24.86 M
|
$27.78 M
|
$24.77 M
|
$24.36 M
|
$19.01 M
|
$14.77 M
|
$16.65 M
|
$8.26 M
|
$10.11 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$972.00 K
|
$941.00 K
|
$356.00 K
|
$280.00 K
|
$290.02 K
|
$328.76 K
|
$218.31 K
|
$100.61 K
|
$52.64 K
|
$43.50 K
|
| EBITDA |
-$19.19 M |
-$22.83 M |
-$24.23 M |
-$24.46 M |
-$23.92 M |
-$18.59 M |
-$14.43 M |
-$16.40 M |
-$8.20 M |
-$9.87 M |
| EBITDA Ratio |
0
|
-20.83
|
-7.6
|
-741.06
|
-151.05
|
-207.01
|
-120.49
|
-109.57
|
0
|
-50.74
|
| Operating Income Ratio |
0
|
-21.68
|
-7.71
|
-749.55
|
-152.88
|
-210.67
|
-122.31
|
-110.25
|
0
|
-50.96
|
| Total Other Income/Expenses Net |
$262.00 K
|
$824.00 K
|
$3.59 M
|
$1.45 M
|
$1.76 M
|
$1.55 M
|
$56.55 K
|
$658.96 K
|
$658.40 K
|
$776.10 K
|
| Income Before Tax |
-$24.33 M
|
-$22.94 M
|
-$21.00 M
|
-$23.28 M
|
-$22.45 M
|
-$17.37 M
|
-$14.59 M
|
-$15.84 M
|
-$7.60 M
|
-$9.14 M
|
| Income Before Tax Ratio |
0
|
-20.93
|
-6.59
|
-705.55
|
-141.77
|
-193.43
|
-121.84
|
-105.84
|
0
|
-46.97
|
| Income Tax Expense |
-$80.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$506.92 K
|
-$356.96 K
|
$0.00
|
$0.00
|
| Net Income |
-$24.25 M
|
-$22.94 M
|
-$21.00 M
|
-$23.28 M
|
-$22.45 M
|
-$17.37 M
|
-$14.08 M
|
-$15.49 M
|
-$7.60 M
|
-$9.14 M
|
| Net Income Ratio |
0
|
-20.93
|
-6.59
|
-705.55
|
-141.77
|
-193.43
|
-117.6
|
-103.46
|
0
|
-46.97
|
| EPS |
-4.98 |
-5.28 |
-3 |
-5.04 |
-5.23 |
-5.37 |
-7.18 |
-8.56 |
-6.59 |
-8.87 |
| EPS Diluted |
-4.98 |
-5.28 |
-3 |
-5.04 |
-5.23 |
-5.37 |
-7.18 |
-8.56 |
-6.59 |
-8.87 |
| Weighted Average Shares Out |
$4.87 M
|
$4.35 M
|
$4.34 M
|
$4.20 M
|
$3.94 M
|
$2.90 M
|
$1.96 M
|
$1.81 M
|
$1.15 M
|
$1.03 M
|
| Weighted Average Shares Out Diluted |
$4.87 M
|
$4.35 M
|
$4.34 M
|
$4.20 M
|
$3.94 M
|
$2.90 M
|
$1.96 M
|
$1.81 M
|
$1.15 M
|
$1.03 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
